PharmaEssentia Corporation
6446
Pozycja w akcjach
#1451
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Cena akcji
$35.96
Kapitalizacja rynkowa
$14.87B
Zmiana (1 dzień)
-0.85%
Zmiana (1 rok)
138.77%
Kraj
TW
Handel PharmaEssentia Corporation (6446)
Kategoria
Healthcare
Historia ceny akcji dla PharmaEssentia Corporation (6446)
Najwyższa cena zamknięcia: $37.51 dnia 2026-10-01
Najniższa cena zamknięcia: $4.95 dnia 2014-03-01
Najniższa cena zamknięcia: $4.95 dnia 2014-03-01
Historia cen akcji firmy PharmaEssentia Corporation od 2014 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.15 | 20.52% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $212.49 | 24.09% |
CH
|
|
| $7.02 | -23.31% |
CN
|
